COMMUNIQUÉS West-GlobeNewswire

Precision Optics Reports First Quarter Fiscal Year 2026 Financial Results
13/11/2025
Conference Call Scheduled for today, November 13, 2025, at 5:00pm ET GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced [...]
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants
13/11/2025
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of [...]
Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations
13/11/2025
Sales Revenue Up 135% over Q3 2024 FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on the cardiac [...]
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
13/11/2025
Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external [...]
NANOBIOTIX annonce les avancées de sa plateforme de nanoprimer Curadigm avec une mise à jour des plans de développement pour son pipeline interne et des collaborations externes
13/11/2025
Quatre nouvelles demandes de brevets déposées visant à étendre la propriété intellectuelle de la plateforme de nanoprimer Curadigm et contribuer au premier pipeline interne et propriétaire de produits associés avec un [...]
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
13/11/2025
Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can effectively [...]
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
13/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated [...]
Sienna Reports Third Quarter 2025 Financial Results and Continues Growth in Greater Toronto Area
13/11/2025
MARKHAM, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and nine months ended September 30, 2025. [...]
Nyxoah Reports Third Quarter 2025 Financial and Operating Results
13/11/2025
REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. [...]
Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025
13/11/2025
INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025 Lancement réussi aux États-Unis. Les premières implantations commerciales de Genio, largement prises [...]
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
13/11/2025
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the [...]
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
13/11/2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to [...]
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
13/11/2025
Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of [...]
SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates
13/11/2025
Business highlights include: Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Commercial use of QUELIMMUNE therapy demonstrates positive survival [...]
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
13/11/2025
– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted [...]
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
13/11/2025
September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Nov. 13, 2025 [...]
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
13/11/2025
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader- [...]
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
13/11/2025
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
13/11/2025
PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]

Pages